Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$20.35 -0.3%	$19.22	$14.40 ▼ $47.00	$1.35B	1.33	926,727 shs	1.89 million shs
EBS Emergent BioSolutions	$6.61 -0.9%	$5.61	$4.02 ▼ $15.10	$358.78M	2.1	1.79 million shs	845,806 shs
INVA Innoviva	$21.40 +0.1%	$18.90	$15.69 ▼ $21.98	$1.34B	0.37	672,743 shs	1.44 million shs
MNKD MannKind	$3.83 -1.3%	$4.50	$3.81 ▼ $7.63	$1.16B	1.02	2.39 million shs	1.86 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-2.39%	+3.81%	+1.19%	+1.39%	-42.59%
EBS Emergent BioSolutions	-0.82%	+5.20%	+14.13%	+21.12%	+3.01%
INVA Innoviva	-0.74%	+2.35%	+14.83%	+22.89%	+34.40%
MNKD MannKind	-1.02%	-10.80%	-19.33%	-24.66%	-16.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.9167 of 5 stars	4.5	3.0	0.0	3.4	0.0	0.0
EBS Emergent BioSolutions	4.366 of 5 stars	3.5	2.0	4.6	2.1	2.5	1.3
INVA Innoviva	4.145 of 5 stars	3.5	0.0	4.2	2.6	1.7	1.9
MNKD MannKind	3.0811 of 5 stars	3.6	1.0	0.0	3.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.90	Moderate Buy	$53.90	164.86% Upside
EBS Emergent BioSolutions	3.00	Buy	$14.33	116.84% Upside
INVA Innoviva	3.00	Buy	$55.00	157.01% Upside
MNKD MannKind	3.25	Buy	$10.00	161.10% Upside

Current Analyst Ratings Breakdown

Latest EBS, CLDX, INVA, and MNKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
4/10/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$12.00
4/9/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/1/2025	EBS Emergent BioSolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/21/2025	EBS Emergent BioSolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/20/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$46.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.56M	178.72	N/A	N/A	$9.08 per share	2.24
EBS Emergent BioSolutions	$930.30M	0.39	$0.74 per share	8.92	$12.51 per share	0.53
INVA Innoviva	$369.84M	3.63	$4.14 per share	5.17	$10.66 per share	2.01
MNKD MannKind	$297.60M	3.91	N/A	N/A	($0.91) per share	-4.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$141.43M	-$2.70	N/A	N/A	N/A	-1,544.32%	-19.75%	-18.86%	8/6/2025 (Estimated)
EBS Emergent BioSolutions	-$760.50M	-$2.71	N/A	3.19	N/A	-18.55%	-9.91%	-3.31%	8/5/2025 (Estimated)
INVA Innoviva	$179.72M	-$1.01	31.01	13.81	N/A	18.31%	20.84%	11.38%	7/29/2025 (Estimated)
MNKD MannKind	-$11.94M	$0.10	54.71	16.65	N/A	8.07%	-17.74%	8.68%	8/6/2025 (Estimated)

Latest EBS, CLDX, INVA, and MNKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/7/2025	Q1 2025	EBS Emergent BioSolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
EBS Emergent BioSolutions	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	24.27	24.27
EBS Emergent BioSolutions	1.30	2.88	1.47
INVA Innoviva	0.38	1.79	1.64
MNKD MannKind	N/A	4.54	4.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
EBS Emergent BioSolutions	78.40%
INVA Innoviva	99.12%
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	3.80%
EBS Emergent BioSolutions	3.20%
INVA Innoviva	2.25%
MNKD MannKind	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.82 million	Optionable
EBS Emergent BioSolutions	2,420	54.28 million	53.53 million	Optionable
INVA Innoviva	100	62.78 million	61.54 million	Optionable
MNKD MannKind	400	303.93 million	267.51 million	Optionable

EBS, CLDX, INVA, and MNKD Headlines

Recent News About These Companies

Insider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares of Stock

June 11 at 6:48 AM | insidertrades.com

Brokers Set Expectations for MannKind FY2026 Earnings

June 11 at 2:23 AM | americanbankingnews.com

Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD)

June 10 at 10:10 PM | gurufocus.com

MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares

June 10 at 8:40 PM | marketbeat.com

MannKind’s Strategic Growth Potential and Market Positioning: A Buy Recommendation

June 10 at 2:41 PM | tipranks.com

MannKind (NASDAQ:MNKD) Sets New 1-Year Low - Time to Sell?

June 10 at 11:35 AM | marketbeat.com

Cantor Fitzgerald Estimates MannKind FY2026 Earnings

June 10 at 8:56 AM | marketbeat.com

MannKind Corp (MNKD) to Showcase Inhaled Insulin at ADA's 85th Scientific Sessions | MNKD stock news

June 9 at 5:44 PM | gurufocus.com

MannKind Corporation to Showcase Inhaled Insulin Innovations at ADA's 85th Scientific Sessions

June 9 at 4:26 PM | quiverquant.com

MannKind to present inhaled insulin study at ADA event

June 9 at 4:26 PM | investing.com

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

June 9 at 4:05 PM | globenewswire.com

MannKind (NASDAQ:MNKD) Cut to Hold at Wall Street Zen

June 9 at 2:33 AM | americanbankingnews.com

MannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street Zen

June 7, 2025 | marketbeat.com

180 Wealth Advisors LLC Has $11.04 Million Holdings in MannKind Co. (NASDAQ:MNKD)

June 2, 2025 | marketbeat.com

MannKind Co. (NASDAQ:MNKD) Given Average Recommendation of "Buy" by Brokerages

May 31, 2025 | marketbeat.com

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025 | globenewswire.com

Voloridge Investment Management LLC Has $6.86 Million Stake in MannKind Co. (NASDAQ:MNKD)

May 27, 2025 | marketbeat.com

Nuveen Asset Management LLC Lowers Stake in MannKind Co. (NASDAQ:MNKD)

May 27, 2025 | marketbeat.com

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

May 27, 2025 | seekingalpha.com

Two Sigma Advisers LP Boosts Stock Holdings in MannKind Co. (NASDAQ:MNKD)

May 24, 2025 | marketbeat.com

Two Sigma Investments LP Boosts Stock Holdings in MannKind Co. (NASDAQ:MNKD)

May 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS, CLDX, INVA, and MNKD Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$20.35 -0.07 (-0.34%)

As of 04:00 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Emergent BioSolutions NYSE:EBS

$6.61 -0.06 (-0.90%)

As of 03:59 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Innoviva NASDAQ:INVA

$21.40 +0.03 (+0.14%)

As of 04:00 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

MannKind NASDAQ:MNKD

$3.83 -0.05 (-1.29%)

As of 04:00 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time